Ryan founded Oxford Genetics in 2011 with the aim to revolutionize DNA design, optimisation and assembly to enable molecular engineering to fulfil its promise in synthetic biology and medicine. Ryan has a first class degree in Genetics and a Ph.D. from Oxford University. He is an experienced genetic engineer with extensive knowledge and practical insight working with bacterial, botanical and mammalian recombinant expression systems.
Ryan's research interests in synthetic biology and molecular engineering include vaccines and treatments for infectious diseases and cancer. He was inspired to create Oxford Genetics after observing that inefficient DNA design and assembly often limit scientific progress.
Paul has over 15 years experience in developing global sales, marketing, business development and licensing strategies for life science product and service-based business models. Paul holds a BSc in biochemistry from the University of Wales, a PhD in molecular biology from the University of Manchester, and a MBA from the University of Nottingham.
Prior experience includes senior management positions in both the USA and Europe, including Head of Discovery Services at Sigma-Aldrich, where he led teams involved in the successful commercialization of several functional genomic technologies, including the world’s first commercial gene editing technology and custom cell line engineering service.
Tom has >10 years commercial experience in biopharmaceutical development and bioproduction, having held R&D and commercially-focused roles at both Novozymes Biopharma (now Albumedix) and Lonza in the UK.
At Oxford Genetics, Tom is responsible for technology development activities, spanning the breadth of services and products offered. His research interests include gene editing, synthetic biology and cellular engineering. Tom holds a BSc and Ph.D in Molecular Biology from the University of Nottingham.
Martin joined Oxford Genetics in November 2017 and has more than 30 years financial and general management experience in technology and IP-focused businesses. He specialises in leading and developing small technology organisations through periods of rapid growth, fund-raising and international expansion to exit events including trade sale or preparation for IPO. Martin’s most recent role was CFO of Warwick-based Allinea Software, culminating in the successful sale of the business with an average return to shareholders of 100 x net investment.
Prior experience includes fourteen years as global Head of Finance of Oxfordshire-headquartered Sophos - during which time the business grew from £2 million turnover and 15 employees to over £100 million turnover and 1,100 employees. Martin qualified as a Chartered Accountant with Price Waterhouse in London and holds a MA degree in Economics from the University of Cambridge.